Is Continuous Therapy Becoming Finite? The Evolving Landscape of CLL Treatment in 2026
Canadian Hematology Today · 10.06.2026 · 37-43
DOI: 10.58931/cht.2026.5186 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Hematology Today, online erschienen am 10.06.2026. Verfasst von Stephanie Craig und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The front-line treatment landscape for chronic lymphocytic leukemia (CLL) is rapidly evolving, with several new therapeutic options emerging. Traditionally, chemoimmunotherapy (CIT) formed the foundation of front-line treatment. However, over the past decade, targeted therapies have transformed the management of CLL, replacing CIT as the backbone of front-line treatment. Table 1 summarizes pivotal trials that have advanced CLL treatment. As a result of these advances, clinicians now have multiple highly effective frontline options. The challenge is no longer selecting the most efficacious regimen but rather selecting the optimal strategy for each individual patient. To address this evolving landscape, this review highlights current evidence and key practical considerations shaping frontline CLL management in Canada.
Zitieren
APA
Craig, S., & Murphy, S. (2026). Is Continuous Therapy Becoming Finite? The Evolving Landscape of CLL Treatment in 2026. Canadian Hematology Today, 37-43. https://doi.org/10.58931/cht.2026.5186
Vancouver
Craig S, Murphy S. Is Continuous Therapy Becoming Finite? The Evolving Landscape of CLL Treatment in 2026. Canadian Hematology Today. 2026:37-43. doi:10.58931/cht.2026.5186
BibTeX
@article{Craig2026,
author = {Craig, Stephanie and Murphy, Shannon},
title = {Is Continuous Therapy Becoming Finite? The Evolving Landscape of CLL Treatment in 2026},
journal = {Canadian Hematology Today},
year = {2026},
pages = {37--43},
doi = {10.58931/cht.2026.5186}
}
EUVIMED